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Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart
failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the
myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate
into restored cardiac function and improved patient survival. For this purpose, we developed
the selective anti-ATTR antibody NI301A, a recombinant human monoclonal immunoglobulin
G1. NI301A was cloned following comprehensive analyses of memory B cell repertoires
derived from healthy elderly subjects. NI301A binds selectively with high affinity to the
disease-associated ATTR aggregates of either wild-type or variant ATTR related to sporadic
or hereditary disease, respectively. It does not bind physiological transthyretin. NI301A
removes ATTR deposits ex vivo from patient-derived myocardium by macrophages, as well
as in vivo from mice grafted with patient-derived ATTR fibrils in a dose- and time-dependent
fashion. The biological activity of ATTR removal involves antibody-mediated activation of
phagocytic immune cells including macrophages. These data support the evaluation of safety
and tolerability of NI301A in an ongoing phase 1 clinical trial in patients with ATTR
cardiomyopathy.
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ransthyretin (TTR) amyloidosis is a systemic disease
characterized by the accumulation of TTR amyloid
(ATTR) in myocardium, peripheral nerves, and various
other tissues, causing congestive heart failure, polyneuropathy,
and death1. Sporadic and hereditary forms of the disease are
characterized by the deposition of wild-type TTR (TTRwt) and
mutated variants of TTR (TTRv), respectively. TTR is a hepatic
thyroxine and retinol-transporting protein secreted into the
blood2. It can partially unfold and aggregate into ATTR fibrils;
these consists of stable β-pleated sheet structures3. Extracellular
myocardial ATTR deposits accumulate in massive amounts
impacting such mechanical properties of the myocardium as
diastolic relaxation followed by systolic impairments during
progression of the disease. In peripheral sensorimotor neurons,
ATTR deposits are causing polyneuropathy, which are, together
with cardiomyopathy, the major clinical manifestations of TTR
amyloidosis4. Most sporadic and many genetic amyloidosis are
associated with both cardiomyopathy and polyneuropathy. Rare
pure forms of either syndrome include the TTR V122I variant
with dominating cardiomyopathy and the TTR-V30M variant
predominantly associated with polyneuropathy5. Epidemiological
studies indicate that TTR amyloidosis with cardiomyopathy
(ATTR-CM) is likely massively underdiagnosed. Data from Fin-
land, USA, Spain, and France consistently indicate that cardiac
TTR amyloidosis causes 5–13% of all heart failures with preserved
ejection fraction or hypertrophic cardiomyopathies6–11.
Current treatments of TTR amyloidosis include stabilization of
TTR in its naturally folded physiological form and gene silencing,
thus preventing unfolding, aggregation, and deposition in target
tissues12. To remove pre-existing ATTR from affected tissues in
patients with TTR amyloidosis, we developed the human
monoclonal antibody NI301A selectively targeting ATTR aggre-
gates. By using high-throughput screening of human memory
B-cell libraries, we generated a collection of ATTR-binding
antibodies selected for high-affinity binding to ATTR, amyloid-
removal activity, and absent binding to naturally folded,
physiological TTR. This functional selection process led to the
identification of NI301A. NI301A binds to the linear epitope
WEPFA hidden in TTR’s naturally folded conformation, but
accessible to antibody binding following unfolding and aggrega-
tion. NI301A binds ATTR deposits in cardiac tissues obtained at
autopsy from ATTR-CM patients and triggers ATTR removal
from the post-mortem tissues ex vivo via phagocytosis through
added human macrophages. In wild-type mice grafted with
patient-derived ATTR fibrils, systemically administered NI301A
accumulates on the grafts and rapidly removes them via Fcγ-
mediated phagocytosis. Together, these data support the clinical
testing of NI301A (NI006) in patients with ATTR-CM in an
ongoing phase 1 clinical trial (NCT04360434).
Results
NI301A selectively binds human ATTR. NI301A bound with
high affinity and specificity both ATTRwt and ATTRv aggregates,
without binding to their native physiological conformation.
In enzyme-linked immunosorbent assays (ELISAs) against
human ATTR fibrils prepared in vitro (Fig. 1a) and coated to assay
plates, NI301A bound ATTRwt, as well as ATTR-V30M and ATTR-
V122I, with high affinities as indicated by EC50 values in the sub-
nanomolar range (EC50 for ATTRwt= 0.35 nM, ATTR-V30M=
0.38 nM, and ATTR-V122I= 0.15 nM; Fig. 1b). NI301A bound
similarly to fibrils of ATTR-V20I, L55P, S112I, and S116Y (EC50 for
ATTR-V20I= 0.14 nM, ATTR-L55P= 0.61 nM, ATTR-S112I=
0.20 nM, and ATTR-S116Y= 0.24 nM; Fig. 1b).
To confirm aggregate selectivity independently of high-density
coating, fibrils were presented in solution by using a sandwich
ELISA format. Again, NI301A bound with high affinity to ATTR
oligomers with EC50 values in the low nanomolar range (EC50 for
ATTRwt= 3.7 nM, ATTR-V30M = 12.8 nM and for ATTR-
V122I= 3.7 nM). NI301A did not bind to native TTR tetramers
in their physiological conformation (Fig. 1c).
Surface plasmon resonance (SPR) analyses of binding kinetics
showed that NI301A bound ATTRwt oligomers in solution with
an equilibrium dissociation constant (KD) of 1.2 nM, with rapid
association and slow dissociation (ka= 2.1 × 104 M−1s−1, kd=
2.6 × 10−5 s−1; Fig. 1d). Biolayer interferometry (BLI) yielded
similar results for ATTRv: NI301A bound ATTR-V30M oligomers
in solution with a KD of 2.5 nM (ka= 1.7 × 104M−1s−1, kd=
4.3 × 10−5 s−1) and ATTR-V122I oligomers with a KD of 3.6 nM
(ka= 2.2 × 104M−1s−1, kd= 7.8 × 10−5 s−1; Fig. 1e). Consistent
with its conformation selectivity indicated by sandwich ELISA,
NI301A did not bind physiological native tetramers of either
TTRwt or TTRv.
NI301A’s selectivity for ATTR was further confirmed by dot
blot analyses: NI301A bound fibrils of ATTRwt and ATTR-V20I,
V30M, L55P, S77Y, S112I, Y116S, T119M, and V122I immobi-
lized on nitrocellulose membranes, but not the cognate native
TTR tetramers (Fig. 1f). In contrast, a non-selective control anti-
TTR antiserum (Dako A0002) bound both ATTR fibrils and
native TTR tetramers.
Using overlapping peptide arrays, the NI301A-binding epitope
was determined as the linear peptide sequence WEPFA located in
position 41–45 of mature TTR protein (Supplementary Fig. 1).
Time-course aggregation studies of in vitro-generated ATTR-
V30M fibrils separated by semi-native polyacrylamide gel
electrophoresis (PAGE) characterized NI301A binding to specific
oligomeric ATTR species: NI301A bound dimers, trimers,
tetramers, as well as higher-order ATTR aggregates (Fig. 1g).
As expected, NI301A did not react with native TTR tetramers but
detected misfolded ATTR monomers exposing the NI301A-
binding epitope that is hidden in the native monomer. In
contrast, the non-selective control antiserum Dako A0002 bound
both the misfolded monomer and the native tetramer. The
antibody 39-44, described as an amyloid-selective TTR
antibody13, robustly bound dimers and small ATTR oligomers
but only poorly to larger ATTR oligomers with residual binding
to native TTR tetramers.
The absence of binding to physiological TTR tetramers was
further investigated in a series of immunoprecipitation experi-
ments. Whereas Dako A0002 immunoprecipitated native TTR
from human plasma even at 1 : 10,000 dilution, NI301A failed to
immunoprecipitate TTR from the plasma (Fig. 1h and Supple-
mentary Fig. 2).
NI301A binds ATTR deposits on patient tissues. Immunohis-
tochemistry (IHC) showed that NI301A bound with high-
selectivity ATTR deposits on a collection of fresh frozen cardiac
tissues obtained at autopsy from patients with sporadic ATTR-
CM (Fig. 2a). Consistent with its high selectivity for ATTR,
NI301A failed to bind to cardiac non-ATTR deposits (A+TTR−),
likely representing light-chain amyloid.
IHC staining with NI301A of fresh frozen salivary gland
biopsies collected from ATTR T49I, T60A, I68L, S77T, or V122I
mutation carriers showed a pronounced staining of ATTR
deposits in all patients analyzed (Fig. 2b). Furthermore, NI301A
bound ATTR deposits in skin biopsies and abdominal fat
aspirates collected from hereditary cases of ATTR-V30M
amyloidosis with polyneuropathy (Fig. 2c, d). In contrast to the
non-selective anti-TTR antiserum Dako A0002, NI301A did not
bind to native TTR expressed in pancreatic α-cells (Fig. 2c),
confirming further the amyloid selectivity of NI301A.
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On patient myocardium amyloid extracts, NI301A reacted with
high sensitivity to small, medium, and large ATTR aggregates,
consistent with our results with ATTR-V30M aggregates
prepared in vitro. Consistent with its ATTR selectivity, NI301A
did not bind corresponding preparations from cardiac tissues
without amyloid deposits (A−) or amyloid deposits unrelated to
TTR (A+TTR−) (Fig. 3). Selective binding to ATTR aggregates
together with absent binding to unrelated proteins was sustained
following long exposure, further underscoring NI301A’s high
degree of selectivity (Supplementary Fig. 3).
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Fig. 1 NI301A binds to wild-type and mutant ATTR fibrils in vitro, with absent binding to native TTR tetramers. a Characterization of ATTRwt fibrils
prepared in vitro: fibrils were visualized by electron microscopy after 72 h and bound the amyloid indicator dye thioflavin T. b NI301A binding to coated
ATTRwt and ATTRv fibrils by ELISA (symbols: mean of duplicates, lines: data fitting). c Sandwich ELISA using NI301A for capture and detection to measure
in-solution binding to ATTR and TTR tetramers (mean of duplicates). d SPR analysis of NI301A-binding kinetics to ATTRwt oligomers and native TTRwt
tetramers in solution. e BLI analysis of NI301A-binding kinetics to ATTR-V30M and ATTR-V122I oligomers, and native TTRv tetramers in solution. For d
and e, data (gray to black) were fitted with a 1 : 1 binding model (red lines). f Dot blot analysis of NI301A binding to native tetramers or amyloid aggregates
of TTRwt and TTRv proteins. A polyclonal, pan-TTR antibody (Dako A0002) was used for comparison. g Analysis of TTR-V30M aggregation time course
by semi-native SDS-PAGE followed by western blotting with antibodies NI301A, 39-44, and Dako A0002. Positions of ATTR monomers (1), dimers (2),
trimers (3), tetramers (4), and aggregates of high molecular weight (HMW) are marked. h Immunoprecipitation with antibodies NI301A, Dako A0002, and
human IgG1 isotype control of native TTR tetramers (tetr.TTR) or patient-derived ATTR fibrils (ATTR fibr.), and serial dilutions of human plasma from
healthy donors.
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Fig. 2 NI301A binds TTR amyloid present in sporadic and hereditary cases of ATTR amyloidosis with cardiomyopathy and polyneuropathy. a IHC
using NI301A on frozen post-mortem heart tissues collected from three sporadic cases with ATTRwt cardiomyopathy, a case without amyloid (A−), and
one with non-TTR amyloid deposits (A+TTR−). ATTR deposits were identified by Congo red staining with birefringence and immunostaining with the pan-
TTR antibody Dako A0002. b IHC using NI301A and Congo red staining on frozen salivary gland biopsies collected from ATTRv cardiomyopathy patients
carrying the variants TTR-T49I, T60A, I68L, S77T, and V122I. c IHC using NI301A and Dako A0002 on skin biopsy from a patient with ATTR-V30M
polyneuropathy and on human pancreas tissue. d IHC using NI301A and Dako A0002 on abdominal fat aspirates from two patients with ATTR-V30M
polyneuropathy.
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The selectivity of NI301A was further confirmed in a human
tissue cross-reactivity study using fresh frozen human tissue
arrays. This study did not identify any off-target binding for
NI301A at 30 µg/mL, the highest concentration tested. No
staining was observed on liver tissue sections, the main organ
producing TTR, further confirming NI301A absent binding to
physiological TTR protein (Supplementary Fig. 4).
NI301A removes ATTR fibrils by macrophage-mediated pha-
gocytosis. By using human macrophages freshly prepared from
peripheral blood mononuclear cells, we established NI301A’s
biological activity to trigger phagocytosis of fluorescent TTR-
L55P aggregates. We used TTR-L55P because of its ability to
oligomerize under physiological conditions. NI301A triggered
ATTR-L55P phagocytosis in a concentration-dependent manner,
with activity starting at low nanomolar antibody concentrations.
Antibody-mediated phagocytosis of ATTR-L55P oligomers was
impeded by blocking Fc receptors consistent with Fc-mediated
phagocytosis. An isotype control antibody failed to trigger pha-
gocytosis of ATTR-L55P (Fig. 4a). Flow cytometry experiments
with ATTR-L55P and antibodies labeled with different fluor-
escent dyes showed that NI301A, but not the isotype control
antibody, dose-dependently triggered the phagocytosis of ATTR-
L55P oligomers by macrophages (Fig. 4b and Supplementary
Fig. 5). Confocal microscopy of human macrophages during
phagocytosis revealed intracellular vesicular localizations of
ATTR-L55P and NI301A, suggesting co-localization of ATTR-
L55P and NI301A within vesicles (Fig. 4b3).
Amyloid deposits in patients consist of multiple proteins,
proteoglycans, and the plasma protein Serum Amyloid P (SAP),
potentially masking ATTR epitopes. To verify that NI301A
triggers phagocytosis of patient amyloid deposits, we developed
an ex vivo functional assay with fresh frozen myocardium
sections containing ATTR and incubated them with human
macrophages in the presence of antibodies. During 14 days of
incubation, NI301A removed ATTR from human myocardium in
a concentration-dependent manner. NI301A reduced both the
total number of ATTR deposits and the total area covered by
ATTR deposits by up to 50% (Fig. 4c, d). ATTR removal from
patient myocardium tissue sections was specific for NI301A; the
isotype control antibody failed to remove ATTR.
NI301A-mediated complement activation accelerates amyloid
clearance. To further characterize NI301A’s amyloid-removal
activity, we evaluated the impact of complement activation on
amyloid clearance. Phagocytosis assays were done in the presence
or the absence of different concentrations of either fresh or heat-
inactivated human plasma. Human plasma triggered a
concentration-dependent increase in ATTR-L55P phagocytosis
in vitro; heat inactivation of plasma abolished this activity
(Fig. 5a). The acceleration by fresh plasma of ATTR phagocytosis
was confirmed in ex vivo assays, resulting in an almost complete
removal of cardiac amyloid deposits by macrophages (Fig. 5b). In
vitro experiments further confirmed complement activation:
NI301A binding to coated ATTRwt fibrils in the presence of fresh
human plasma triggered formation of the insoluble complement
factor C5b9, indicating that the complement cascade had been
activated to completion (Fig. 5c). No complement activation
occurred when NI301A was incubated with BSA and plasma,
consistent with a specific effect of NI301A decorating ATTR
fibrils.
NI301A binds ATTR fibrils in vivo and activates amyloid
clearance in mice. To characterize the biological activity of
NI301A in vivo, we developed a patient-derived amyloid xenograft
(PDAX) mouse model. In PDAX mice, ATTR fibrils extracted
from patient myocardium tissues were subcutaneously grafted and
fluorescent NI301A-VT680 conjugates were injected intravenously
(i.v.), to determine the target engagement of human amyloid in
living mice (Fig. 6a). Human ATTR fibril grafts were thioflavin S-
positive, indicating preserved β-sheet conformation of the ATTR
amyloid deposits. Forty-eight hours after grafting and i.v. antibody
administration, fluorescent NI301A-VT680 dose-dependently
accumulated on human ATTR fibril grafts and colocalized with
thioflavin S, indicating that it bound to human amyloid in vivo
(Fig. 6b). The NI301A-VT680 fluorescence intensity increased
linearly with dose over the range of 0.05–15mg/kg, indicating that
epitopes for antibody binding were not saturated with doses up to
15mg/kg body weight (Fig. 6c).
For in vivo efficacy experiments, we produced the monoclonal
mouse chimeric antibody ch.NI301A by fusing the human
NI301A variable domains with murine IgG2a constant domain
sequences. Six hours and 96 h following fibril grafting and
injection of ch.NI301A, we measured ATTR by IHC. After 6 h of
antibody treatment, mice presented similar amounts of ATTR per
graft, corresponding to an average 86% of the graft area (range
83.2–89.7%). At this early time point, the fibril grafts were
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Fig. 3 NI301A binds small and large ATTRwt aggregates extracted from patient tissues. Semi-native SDS-PAGE analysis of the amyloid fibril extracts
prepared from frozen post-mortem cardiac tissues presenting TTR amyloid (ATTR+ samples, #1–4), no amyloid (A− samples, #5–8), or non-TTR amyloid
(A+TTR− sample, # 9). Identical SDS-PAGE gels were processed for western blot analysis with the antibodies NI301A, 39-44, and Dako A0002, or stained
with the silver method. The low ATTR staining intensity of sample 4 is consistent with the low amount of TTR amyloid observed by IHC in this sample.
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immediate response characteristic of wound-healing process
(Supplementary Fig. 6). After 96 h, the isotype-treated control
group showed a moderate, but statistically significant, decrease in
graft ATTR area, reflecting a spontaneous reaction against the
human ATTR fibril grafts. All three doses (0.5, 5, and 50 mg/kg
body weight) of ch.NI301A further reduced ATTR in a dose-
dependent manner. Both the 5 and 50 mg/kg doses removed the
amyloid fibrils almost completely, down to background levels of
about 7% of the graft area. Even the low dose of 0.05 mg/kg ch.
NI301A trended to remove amyloid, but its effect was not
statistically significant (Fig. 6d). At this late time point (96 h),
ATTR fibril grafts were entirely infiltrated by phagocytic
monocytes (CD11B+, LY6G−, IBA1−) (Supplementary Fig. 6).
Mice did not exhibit any sign of overt toxicity.
Collectively, the linear increase in target binding over the range
of 0.05–15 mg/kg and the strong biological activity starting at
doses of 5 mg/kg body weight suggested that target saturation was
not required for the maximum activation of fibril removal by
phagocytic immune cells in PDAX mice.
A similar in vivo experiment was performed using the Fc-
inactive variant ch.NI301A-LALAPG at 10 mg/kg i.v. In contrast
to treatment with ch.NI301A, which triggered ATTR fibril
removal, treatment with ch.NI301A-LALAPG had no effect on
fibril removal in vivo, indicating that effector functions are
required for antibody-mediated amyloid clearance (Fig. 6e).
The effect of ch.NI301A was also evaluated at 10 mg/kg i.v. in
the presence of the TTR stabilizer tafamidis, administered daily at
1 mg/kg intraperitoneally (i.p.). ch.NI301A fibril removal activity
was maintained in the presence of tafamidis; tafamidis alone had
no effect on ATTR fibril removal (Fig. 6f).
Frequency of cardiac ATTR in autopsy samples from patients
with heart failure. To investigate the frequency of ATTR cardi-
omyopathy and further test the capacity of NI301A to bind ATTR
in patients, we analyzed 80 autopsy heart tissue samples from
patients who died of heart failure at ages ≥80 years. Varying
amounts of Congo red and TTR antibody 39-44 IHC-positive
ATTR deposits were present in 24 (30%) cases. The abundance of
ATTR deposits was low in 11 samples (14%), moderate in
4 samples (5%), and high in 9 samples (11%) (Supplementary
Table 1 and Supplementary Fig. 7). NI301A detected ATTR
deposits by IHC in all 24 ATTR-positive samples.
Discussion
The results of this study show that NI301A, a human-derived
amyloid-selective antibody targeting both ATTRwt and ATTRv,
removed pathological ATTR deposits from patient myocardium
tissues ex vivo, as well as patient-derived ATTR fibril grafts in
mice in vivo. Characterization of the binding properties of
NI301A demonstrated (1) that NI301A bound ATTR oligomers
and fibrils with sub-nanomolar EC50, (2) that NI301A was highly
selective for the amyloid conformation of TTR, and (3) that
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Fig. 4 NI301A activates ATTR phagocytosis by human macrophages on human heart tissue. a In vitro ATTR phagocytosis assay performed with human-
derived macrophages, fluorescently labeled TTR-L55P protein, and different concentrations of NI301A or isotype control antibodies, with or without Fc-
receptor blocking reagent (FcR block) (mean ± SD of triplicates). b In vitro ATTR phagocytosis with both TTR-L55P and NI301A fluorescent conjugates, and
quantification of double-positive macrophages by FACS. b1 Dot plots; b2 quantification of double-positive cells; b3 representative double-positive
macrophage imaged by confocal microscopy: blue: Dapi, green: TTR-L55P-atto488, red: NI301A-atto550. c Ex vivo tissue amyloid-removal assay
performed with human-derived macrophages and NI301A on patient myocardium sections. Representative pair of adjacent tissue sections treated with
NI301A or vehicle containing thioflavin S-positive amyloid deposits (quantified deposits in green). White arrows point to amyloid deposits removed by
macrophages in the presence of NI301A. d Quantification of thioflavin S-positive amyloid deposit number and total area per tissue section following
treatment with increasing concentrations of NI301A or control. Vehicle n= 24 sections, NI301A n= 6 sections per concentration (mean ± SD). One-way
ANOVA and Dunnett’s multiple comparisons test (mean difference and 95% CI). Number of deposits: F(4, 43)= 4.73, P= 0.003; 1.0 nM vs. Vehicle:
−85.08 (−164.4 to −5.8), *P= 0.031; 10 nM vs. Vehicle: −117.4 (−196.7 to −38.1), **P= 0.0017. Total deposit area: F(4, 43)= 1.91, P= 0.13; 10 nM vs.
Vehicle: −278,662 (−560,983 to 3660), °P= 0.054.
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(Fig. 1). The latter was confirmed by IHC using tissues collected
from patients with sporadic or hereditary ATTR amyloidosis with
cardiomyopathy or polyneuropathy (Fig. 2).
Selective binding to wild-type and variant ATTR oligomers and
fibrils is consistent with results of structural studies showing that
pathogenic mutations in the TTR polypeptide sequence can affect
the stability of native tetramers, thus promoting their dissociation
into monomers. These mutations, however, do not modify the
propensity of TTR to misfold, oligomerize, and aggregate into
amyloid-forming fibrils14, suggesting that the pathogenic
mechanisms of accelerated amyloid formation in the genetic
forms of the disease is related to decreased stability of the native
TTR tetramer.
We confirmed the conformation selectivity of NI301A with
independent assays including sandwich ELISA, BLI and SPR, dot
blot, semi-native PAGE and western blottings, IHC, and immu-
noprecipitation from human plasma (Figs. 1 and 2). This strin-
gent selectivity for pathological TTR conformations results from
NI301A binding a hidden linear epitope, which is not accessible
on the native TTR conformation but becomes accessible upon
misfolding of β-pleated sheets into a loop protruding from the
amyloid core3,15. Conformation selectivity can be further
enhanced by high avidity binding to repetitive epitopes that are
displayed in oligomers and amyloid fibrils as was described for
the β-amyloid-selective antibody aducanumab, which was
generated using a similar approach16. From a clinical perspective,
the absent binding to physiological TTR tetramers and monomers
may be a key requirement for therapeutic efficacy of NI301A, as
off-target binding to native TTR present at high concentration in
plasma could lead to impaired pharmacokinetics and reduced
target engagement with tissue ATTR.
In human cardiomyopathy patients, large amounts of ATTR
deposits accumulate in the myocardium. By using in vitro and
ex vivo systems, we established that NI301A induces ATTR
phagocytosis in an antibody concentration-dependent manner
that is mediated by engagement of Fcγ receptors on human
macrophages (Fig. 4). On heart tissue sections from human car-
diomyopathy patients, NI301A dose-dependently removed tissue
amyloid by triggering phagocytosis by human macrophages,
attaining more than 50% amyloid removal within a 2-week time.
This effect size is substantial, considering the absence of replen-
ishment of macrophages in our ex vivo experiments (Fig. 4). Low
concentrations of fresh human plasma further increased
antibody-mediated amyloid removal from patient tissues, sug-
gesting synergistic effects through complement factors in plasma
(Fig. 5). The complement system can contribute to the clearance
of amyloid in vivo by a combination of direct protease activity
and trans signaling, triggering the formation of macrophage-
derived multinucleated giant cells with the capacity to engulf very























Fig. 5 Antibody-mediated complement activation increases ATTR phagocytosis and tissue amyloid clearance. a In vitro ATTR phagocytosis assay
performed with human-derived macrophages, TTR-L55P-atto488, and NI301A in the presence of fresh or heat-inactivated human plasma at different
concentrations (mean ± SD of quadruplicates). b Ex vivo tissue amyloid-removal assay performed with three concentrations of fresh human plasma.
b1 Representative pairs of adjacent tissue sections treated with NI301A or vehicle. b2 Quantification of number and area of amyloid deposits per tissue
section. n= 5–6 sections per condition (mean ± SD). Two-way ANOVA for main factors Plasma concentration and Antibody, and Bonferroni’s multiple
comparisons test of NI301A to vehicle conditions (mean difference and 95% CI). For the number of ATTR deposits: Plasma concentration: F(2,26)= 16.04,
P < 0.0001; Antibody: F(1,26)= 84.53, P < 0.0001; NI301A vs. Vehicle using 0.8% plasma: −309.4 (−461.5 to −157.3), ***P < 0.0001; NI301A vs. Vehicle
using 2.4% plasma: −302.6 (−454.7 to −150.5), ***P < 0.0001; NI301A vs. Vehicle using 7.2% plasma: −308 (−446.9 to −169.1), ***P < 0.0001; NI301A
vs. Isotype using 7.2% plasma: −238.3 (−367.7 to −109.0), ***P= 0.0007. For total deposit area: plasma concentration: F(2,26)= 6.85, P= 0.0041;
Antibody: F(1,26)= 26.56, P < 0.0001; NI301A vs. Vehicle using 2.4% plasma: −522,593 (−899,939 to −145,246), **P= 0.0046; NI301A vs. Vehicle
using 7.2% plasma: −497,895 (−842,364 to −153,427), **P= 0.0031; NI301A vs. Isotype using 7.2% plasma: −398,001 (−734,405 to −61,596), *P=
0.02. c In vitro complement activation assay of NI301A in fresh human plasma using coated ATTRwt fibrils or bovine serum albumine (BSA) as target,
followed by immunodetection of the complement activation product C5b9 (mean of duplicates).
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fresh, but not heat-inactivated, plasma increased NI301A-
mediated phagocytosis of ATTR by macrophages (Fig. 5).
Finally, NI301A was active in vivo. It accumulated dose-
dependently on human ATTR fibrils grafted into mice. A mur-
inized chimeric variant of NI301A substantially accelerated the
removal of ATTR by phagocytic cells and did not exhibit any
signs of overt toxicity in this model. In good agreement with the
in vitro phagocytosis data, antibody-mediated fibril removal
in vivo was dose-dependent and required an active Fc domain
(Fig. 6). Furthermore, the antibody-mediated fibril removal
activity was maintained in the presence of tafamidis, currently the
only approved therapy for ATTR-CM.
ATTR cardiomyopathy is characterized by large accumulation
of extracellular ATTR fibrils in the myocardium, which can lead
to a doubling of extracellular volumes in patients as compared to
healthy subjects18,19, an increase of the left ventricle wall thick-
ness from <12mm in healthy subjects to >20 mm in advanced
patients20,21, and ATTR deposition occupying 30–40% of the
total myocardium tissue area22. Mechanically, amyloid fibrils are
remarkably rigid and their resistance to rupture has been com-
pared to that of steel23. As a result, the accumulation of ATTR in
the myocardium causes progressive tissue rigidification together
with loss of muscle elasticity. Functionally, this loss in elasticity






























50 mg/kg  
Isotype 96 hours 
#57-40 
0.05 mg/kg  
#52-50 
0.5 mg/kg  
#38-50 #46-30 
5.0 mg/kg  50 mg/kg  
All treatment groups 











ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23274-x
8 NATURE COMMUNICATIONS |         (2021) 12:3142 | https://doi.org/10.1038/s41467-021-23274-x | www.nature.com/naturecommunications
followed by reductions in ejection fraction and heart failure. Both
the reduction in left ventricle ejection fraction and the loss of
contractility are strongly correlated with disease severity and
reduced survival time20,24. Several therapeutic approaches for the
treatment of ATTR amyloidosis are focused on a slowing or the
prevention of amyloid formation. The TTR stabilizers tafamidis
and the repurposed anti-inflammatory drug diflunisal, as well as
TTR gene silencers patisiran and inotersen, have achieved sub-
stantial reductions or even a complete halt in disease
progression25–28. NI301A has a different mode-of-action that is
targeting the active removal of pre-existing amyloid and may
therefore have a potential beyond disease stabilization for func-
tional improvements by decreasing cardiac muscle stiffness and
improving heart contractility and elasticity.
We evaluated the frequency of ATTR cardiomyopathy in
elderly male Caucasian patients who died of heart failure with
preserved ejection fraction and found pathologic amounts of
ATTR in 16% of the samples. This high frequency is consistent
with published data, indicating that ATTR cardiomyopathy is a
massively underdiagnosed condition6–11. NI301A bound ATTR
deposits in all positive tissues, suggesting a broad applicability
across patients.
Antibody-mediated amyloid removal is a novel treatment
modality. It is currently tested in advanced stages of clinical
development with proof-of-mechanism obtained in patients. In
Alzheimer’s disease, the Aβ-targeting antibodies aducanumab and
gantenerumab achieved substantial reductions in Aβ plaque load
in patients29,30. Amyloid removal increased with dose and time. It
was associated with amyloid-related imaging abnormalities,
potentially a correlate of the biological mechanism of antibody-
mediated amyloid removal31. Various other antibodies targeting
amyloid or pathological protein aggregates are under clinical
investigation. These include the α-synuclein aggregate-selective
antibodies cinpanemab and PRX002/RG7935 for the potential
treatment of Parkinson’s disease32, the anti-τ antibody BIIB076
for the potential treatment of Alzheimer’s disease33, and the
misfolded SOD1-selective antibody AP101 for the potential
treatment of amyotrophic lateral sclerosis34. Dezamizumab is a
humanized monoclonal IgG1 antibody binding to native SAP
component, a plasma protein identified in all types of amyloid
deposits. In a phase 1 clinical trial conducted in patients with
systemic amyloidosis, dezamizumab treatment was associated
with signs of organ response such as decreases in liver stiffness,
which were highly consistent with the macrophage‐dependent
phagocytic clearance of amyloid demonstrated in animal
models17,38,39. A phase II trial in patients with cardiac amyloi-
dosis was initiated but terminated prematurely due to an
apparent change in the risk-benefit profile, which might have
been related to dezamizumab binding physiological SAP protein.
Similar to aducanumab, cinpanemab, and AP101, NI301A is an
aggregate-selective antibody that was identified based on immune
repertoire analyses of memory B-cell complements from healthy
elderly subjects. Such antibodies targeting pathogenic conforma-
tions of self-proteins may be generated in response to the age-
associated accumulation of pathological protein aggregates
including various form of amyloid, generating the possibility of a
physiological mechanism, for elimination of misfolded proteins
by engaging immune biology otherwise targeting non-self, foreign
proteins. As a corollary, antibody-mediated removal of ATTR
amyloid from heart tissues may well represent an additional
approach for the treatment of patients with cardiomyopathy
caused by ATTR amyloidosis. To test this possibility, NI301A
(NI006) is currently evaluated in a phase 1 clinical trial in ATTR-
CM patients.
Methods
Antibody identification, cloning, and recombinant expression. cDNA sequences
encoding human ATTR-binding antibodies were derived from a de-identified
blood lymphocyte library collected from healthy elderly subjects. Memory B cells
were isolated and cultivated as described in Sevigny at al.29. Human memory B cells
were CD22+, CD27+ and IgD−, IgM−, CD3−, CD56−, and CD8a−. They were
screened by ELISA for the expression of antibodies binding to wild-type and
variant ATTR. Positive hits were counter-screened to exclude clones cross-reacting
with unrelated amyloid-forming proteins. Selected ATTR-reactive B-cell clones
were subjected to cDNA cloning of IgG heavy and light-chain variable region
sequences, and sub-cloned into expression vectors encoding human IgG1 constant
domain sequences. Expression constructs encoding IgG1 heavy and light chains
were transiently expressed in CHO-S cell line and purified by protein A affinity
chromatography.
Human blood samples from healthy elderly subjects were collected under
written informed consent and study approval by the Ethics Committee of the
Canton of Zurich. The study was compliant with the Helsinki Declaration.
Preparation of human ATTR. Human TTRwt was obtained by purification from
human blood plasma (Bio-Rad). The pathogenic TTR protein variants V20I,
V30M, L55P, S77Y, S112I, Y116S, T119M, and V122I were expressed recombi-
nantly in Escherichia coli (Alexotech and Wako); pure preparations of non-amy-
loid, native TTRwt, and TTRv tetramers were obtained by size-exclusion
chromatography on Superdex 75 columns, to remove pre-existing misfolded pro-
teins. ATTR fibrils were prepared by aggregating TTR at 200 µg/mL in 50 mM
acetate-HCl, 100 mM KCl, 1 mM EDTA pH 3.0 for 5 days at 65 °C under shaking
conditions at 1000 r.p.m.15. This procedure generated thioflavin S-positive fibrils
readily detectable by electron microscopy (Fig. 1a). Water-soluble ATTR oligomers
were prepared with the above protocol and by limiting the aggregation time of TTR
to 4 h at 37 °C.
Enzyme-linked immunosorbent assay. ELISA assays were done in 96-well
microplates (Corning) coated with ATTR fibrils and were blocked with 2% BSA,
0.1% Tween-20 in phosphate-buffered saline (PBS) before adding primary anti-
bodies in duplicates for overnight incubation at 4 °C. After washing, bound anti-
bodies were detected with horseradish peroxidase (HRP)-conjugated anti-human
IgG antibodies (Jackson Immunoresearch) and DAB (3,3'Diaminobenzidine)
substrate. The absorbance was measured using a multifunction plate reader
(ThermoFisher Varioskan Lux and SkanIt 6.02 software). Data were exported to
Fig. 6 Dose-dependent binding of NI301A on TTR amyloid in vivo and activation of immune clearance in mice. a Schematic of the patient-derived
amyloid xenograft mouse model: ATTR fibril graft was placed subcutaneously on the thigh and treatments administered i.v. b In vivo binding of
fluorescently labeled NI301A-VT680 to patient-derived ATTR fibril grafts 48 h after amyloid grafting and antibody administration. c Quantification of
NI301A-VT680 fluorescence intensity on ATTR grafts (mean ± SD of 5 mice per dose level using 3 sections per mouse). d ch.NI301A-mediated clearance
of ATTR grafts in vivo. ATTR remaining after 6 and 96 h of treatment was detected by IHC staining and quantified (mean ± SD of n= 4–5 mice per group
using 3–6 sections per mouse). One-way ANOVA (F(4, 19)= 13.6, P < 0.001) and Dunnett’s multiple comparisons test (mean difference and 95% CI). Ch.
NI301A 0.5 vs. Isotype: −34.3 (−55.0 to −13.6), **P= 0.001; ch.NI301A 5 vs. Isotype: −50.9 (−72.8 to −28.9), ***P < 0.001; ch.NI301A 50 vs. Isotype:
−43.4 (−64.1 to −22.6), ***P < 0.001. e Evaluation of Fc-silent ch.NI301A-LALAPG antibody on ATTR graft removal in vivo (mean ± SD of n= 8 mice per
group using 3–4 sections per mouse, all antibodies at 10mg/kg i.v.). One-way ANOVA (F(2, 21)= 14.2, P= 0.0001) and Dunnett’s multiple comparisons
test. Ch.NI301A vs. isotype: −22.4 (−34.0 to −10.7), ***P= 0.0003. f Evaluation of ch.NI301A+ tafamidis combination on ATTR removal in vivo (mean ±
SD of n= 6–8 mice per group, 3–4 sections per mouse; antibodies once at 10 mg/kg i.v. and tafamidis daily at 1 mg/kg i.p.). Two-way ANOVA for main
factors Antibodies and Stabilizer, and Dunnett’s multiple comparisons test to the isotype+ vehicle group. Antibody: F(1, 25)= 52.3, P < 0.0001; Stabilizer:
F(1, 25)= 0.52, P= 0.48. Ch.NI301A+ vehicle vs. isotype+ vehicle: −23.9 (−38.2 to −9.5), ***P= 0.001; ch.NI301A+ tafamidis vs. isotype+ vehicle:
−31.8 (−46.1 to −17.4), ***P < 0.0001.
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Excel (Microsoft) for data management and were fitted with a logarithmic
dose–response function with variable slope (four parameter logistic regression,
4PL) using the least-square regression in Prism 7.03 (GraphPad).
Capture ELISA. Streptavidin-coated plates (Greiner) were loaded with biotinylated
NI301A and blocked before the addition of ATTR or TTR samples in duplicates for
2 h incubation at room temperature. After washing, bound ATTR was detected
with an HRP-conjugated NI301A antibody in combination with luminescent
substrate (Biotinylation kit, HRP-labeling kit, and HRP substrate from Thermo-
Fisher). Data were fitted using 4PL with 1/y2 weighting.
Binding kinetics assays. Binding to soluble ATTRwt oligomers was determined
by SPR on a ProteOn XPR36 machine (Bio-Rad) at 25 °C in HBS-T buffer, using an
anti-human IgG, Fcγ-specific antibody (Jackson Immunoresearch) covalently
coupled to a GLM sensor chip, to capture NI301A on the sensor. Data were
analyzed in ProteOn Manager v. 2.0 and double-referenced using interspots and
the buffer-only channel, and fitted by using a 1 : 1 kinetic model (Langmuir fit).
Binding to soluble ATTRv oligomers was determined by BLI on an Octet
RED96 machine (Pall ForteBio). As this technology circumvents the need for
microfluidics, it is well suited for measuring binding to protein aggregates. The
experiments were done at 25 °C by using streptavidin sensors preloaded with
biotinylated NI301A or isotype control antibodies. Data were analyzed in
DataAnalysis v.8.2 and double-referenced using isotype and buffer-only conditions,
and fitted using a 1 : 1 kinetic model.
Immunoblottings. For dot blots, 200 ng of TTR tetramers and ATTR fibrils pre-
pared as described above were immobilized on nitrocellulose membranes by using
vacuum filtration. For western blottings, TTR-V30M was aggregated for 4 days at
37 °C under near-physiological conditions in 10 mM citric acid pH 6.0, 150 mM
NaCl, and 5 mM Ca2+. Samples were separated by non-reducing SDS-PAGE with
no heat denaturation, to preserve the aggregates’ sizes, and were immobilized on
nitrocellulose membranes by semi-dry blotting (ThermoFisher). Epitope mapping
was conducted using a cellulose membrane array of 29 overlapping peptides of 15
amino-acid length and 11 amino-acid overlap, which covered the whole mature
TTR protein sequence, and 15 additional peptides which covered the TTR leader
peptide sequence and 13 selected TTR mutations associated with hereditary TTR
amyloidosis. Membranes were blocked, incubated with NI301A overnight at 4 °C,
and developed with HRP-conjugated, anti-human, rabbit or mouse IgG antibodies
(Jackson Immunoresearch) in combination with a chemiluminescent substrate
(ThermoFisher).
Immunoprecipitation. Protein A-coated magnetic beads (Dynabeads, Life Tech-
nologies) were saturated with NI301A or anti-TTR Dako A0002 antibodies and
incubated for 30 min at room temperature with TTRwt tetramers, or with patient-
derived ATTR fibrils functioning as controls, or with human plasma samples
diluted 0, 10, 100, 1000, and 10,000 times in PBS with Tween-20. After washing,
the antibody–antigen complexes were eluted directly in SDS-PAGE loading buffer
(80 °C for 15 min) separated by SDS-PAGE and analyzed by western blotting with
the Dako A0002 TTR antibody.
Immunostaining. Frozen or paraformaldehyde (PFA)-fixed tissue biopsies
obtained from ATTR-CM patients and from ATTR polyneuropathy patients were
stained with Congo red by using Putchler’s modifications35. Immunostainings were
done after quenching endogenous peroxidase activity with 3% H2O2 in methanol,
blocking with 4% BSA and 5% normal horse and goat sera in PBS, incubation with
primary antibodies overnight at 4 °C, and detection using goat anti-rabbit IgG
antibody (Jackson Immunoresearch) where needed, in combination with the
Vectastain ABC kit (Vector Laboratories) and diaminobenzidine (Dako). NI301A
was used as a biotinylated conjugate at 10 nM on frozen tissue sections. Antibody
Dako A0002 was used at 1 : 500 or 1 : 1000 dilutions and required PFA post fixation
for staining, leading to a different appearance of the tissues due to the different
processing. Tissue scanning microscopy was done at ×20 magnification in bright
field and polarization modes with an Olympus VS120 virtual slide microscope.
Immunostaining of PFA-fixed paraffin-embedded ATTR fibril grafts in mice
was performed as described above using the following primary antibodies: Dako
A0002 for TTR, Abcam ab133357 for CD11B, Abcam ab2557 (clone NIMP-R14)
for LY6G, and Wako 019-19741 for IBA1.
Tissue cross-reactivity analyses were conducted by immunostaining using a
biotin-conjugated NI301A antibody at 1, 10, and 30 µg/mL on frozen human tissue
arrays (USBiomax FDA903). The arrays contained 90 tissue sections representing
30 different organs each from three different individuals.
Fibril extraction from tissues. ATTR fibrils were extracted from frozen cardiac
tissues obtained at autopsy and semi-purified using the detergent-free protocol
described by Pras et al.36. This protocol preserves the amyloid conformation by
relying on the partial solubility of amyloid fibrils in pure water.
In vitro and ex vivo phagocytosis assays. Macrophages were differentiated from
fresh human monocytes by culturing these for 10–15 days in macrophage serum-
free medium (M-SFM, Life Technologies) supplemented with macrophage colony-
stimulating factor (100 ng/mL M-CSF, Miltenyi), or granulocyte M-CSF (50 ng/mL
GM-CSF, Sigma).
In vitro phagocytosis was done for 2 h at 37 °C in the presence of fucoidan at 0.5
mg/mL, ATTR-L55P labeled with Atto488 (Sigma) at 7 µg/mL, NI301A, and isotype
control at concentrations from 0 to 80 nM. An Fc-receptor inhibitor (Miltenyi) was
used for negative control at 1 : 100 dilution. After washes, the levels of ATTR-L55P-
atto488 internalization were measured with a fluorescence plate reader (Varioskan
Lux, ThermoFischer). Antibodies labeled with Atto550 (Sigma) were also used in
combination with fluorescence-activated cell sorting to quantify double-positive
macrophages only. All experiments were performed in triplicates. For confocal
microscopy imaging, experiments were done with macrophages coated on coverslips.
Ex vivo phagocytosis was done with human macrophages on 15 µm-thick post-
mortem myocardial sections obtained from ATTR-CM patients. Tissue sections
were mounted on glass coverslips, using pairs of adjacent sections for antibody or
vehicle control conditions. The M-SFM/GM-CSF medium was supplemented with
interferon-γ (100 ng/ml) and lipopolysaccharide (20 ng/ml) to stimulate
macrophage phagocytic activity. Tissue sections (6 replicates per condition) were
incubated for 14 days at 37 °C (95% CO2, 5% O2) with 50% replacement of the cell
culture medium every 3–4 days; they were then directly fixed with 4% PFA, washed,
stained with thioflavin S, and mounted. The full area of the tissue sections was
scanned using an automated slide scanner (Olympus VS120), at ×20 magnification
in both 4′,6-diamidino-2-phenylindole and tetramethylrhodamine channels. Both
numbers of and areas covered by ATTR deposits were quantified by using an
automated image analysis algorithm implemented in a commercial image analysis
software (Image-Pro Premier, Media Cybernetics). Data were analyzed by one-way
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison tests.
For all in vitro and ex vivo experiments with human plasma, plasma was used
either freshly or inactivated by heating at 56 °C for 30 min.
Complement activation assay. ELISA plates coated with ATTRwt fibrils or BSA
were loaded with NI301A and incubated with increasing concentrations of fresh
human plasma for 1 h at 37 °C. After washing, the complement complex C5b9 was
detected with a specific antibody (Abcam) and corresponding secondary antibody
(Jackson Immunoresearch).
PDAX model. Animal experiments were conducted in compliance with the Swiss
federal regulations and received approval from the Swiss Veterinary Service (license
ZH269-14). ATTR fibrils were obtained from post-mortem heart tissues of ATTR-
CM patients using the detergent-free water-based extraction procedure36 and were
prepared at 2 mg/mL concentration to confer high viscosity to the extract. ATTR
fibrils were grafted into SKH1-Elite female mice of 2.5–3 months of age by sub-
cutaneous injection of 50 µL in the thighs followed by i.v. administration of the
antibody. NI301A antibody was labeled with the fluorescent dye VivoTag 680
(Perkin Elmer) for target binding experiments (NI301A-VT680) and the mouse
chimeric IgG2a NI301A variant (ch.NI301A) was used for in vivo efficacy experi-
ments. An Fc-inactive variant, named ch.NI301A-LALAPG, was generated using
the L234A, L235A, and P329G substitutions, which are known to eliminate Fcγ
receptor and complement factor C1 binding37. Tafamidis (Carbosynth) was pre-
pared at 100 µg/mL in vehicle (PBS 7.4, 10% EtOH, 10% PS80) and administered
daily at 1 mg/kg i.p. Data were analyzed by one-way or two-way ANOVAs followed
by Dunnett’s multiple comparisons test using the isotype-treated group as reference.
Human heart tissue analysis. The National Disease Research Interchange collected
the autopsy heart tissues from males with heart failure, with preserved ejection
fraction, who died at an age of 80 years or more. In all cases, the donors (or their next-
of-kin) provided informed consent to procure biospecimens for biomedical research.
Only donors on the Center for Disease Control High Risk category and donors with
cardiac tumors were excluded from the collection. Samples were processed for his-
tological analysis. Congo red-positive samples were stained by IHC with TTR anti-
bodies Dako A0002, 39-44 (Alexotech) and with NI301A as described above.
Statistics and reproducibility. All group values are presented as mean and the SD
represented for groups with n > 3. Statistical analysis were performed using the
GraphPad Prism software, using one-way ANOVA and Dunnett’s multiple com-
parisons test or two-way ANOVA and Bonferroni’s multiple comparison test. P <
0.05 was considered as statistically significant. All experiments have been repeated
on independent occasions and generated similar results.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All unique biological material included in this article can be made available upon
substantiated request to the corresponding author. Source data are provided with
this paper.
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